Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Add Advanced Drug Delivery Technologies Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is being handled by 1 distinct examiner, which centralizes the prosecution process for the company's current intellectual property. The application is assigned to 1 distinct art unit, reflecting a specific technical focus for the pending innovation within the biotechnology field.
LEE, WILLIAM Y is the busiest examiner for the company, overseeing 1 busiest examiner pending office action. This individual is responsible for the 1 busiest examiner pending office action currently active for the portfolio. Consequently, the company's immediate prosecution success is entirely dependent on the decisions and timelines of this 1 distinct examiner within the 1 distinct art unit.
For a patent practitioner, this concentration means that the prosecution strategy should be highly tailored to the specific tendencies of LEE, WILLIAM Y. Since there is only 1 distinct art unit involved, there is no opportunity to compare examination styles across different units for this portfolio. The singular nature of the matters in the Biotechnology & Pharmaceuticals technology area simplifies the management of the portfolio but increases the impact of a single examiner's perspective.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923786 | Uses and Formulations of Cannabinoids | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17923786 | Uses and Formulations of Cannabinoids | LEE, WILLIAM Y | 1623 | §103§112DP | Non-Final OA | — | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdd Advanced Drug Delivery Technologies Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
William Y Lee has the most, with 1 of Add Advanced Drug Delivery Technologies Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
